It's important to remember that crizotinib is not a particularly potent ALK inhibitor - it wasn't originally developed as one in the first place. So hopefully what we are seeing here in terms of resistance are the adverse consequences of using a weak inhibitor up front - the HIV space might provide an instructive analogy.
News 
Market Data 
Discover 
